EMA Recommends Granting a Marketing Authorisation for Nirogacestat By Ogkologos - July 3, 2025 168 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with progressing desmoid tumours Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR News digest – targeted drug approval, microbubble ‘warheads’ and prostate cancer... June 27, 2020 Breast Cancer Survivor Thanks Early Detection For Saving Her Life April 6, 2021 Changes in Metabolism Help Melanomas Spread January 21, 2020 Trial Examines Value of Lymph Node Surgery in Advanced Ovarian Cancer March 27, 2019 Load more HOT NEWS FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole... FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2... New on NCI’s Websites for March 2023 PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients...
